interesting, page-8

Personally I am not watching the clinical results that closely, the expectation is that they will be fine, they have all been so far. And I wouldn't expect more trial results to do much to the share price.

For me the real key is the partnership, will we get one and under what terms. You don't have to look far in the biotech sector to find good products that could not find good deals. TIS are small and do not have much weight to throw around.